Cogent Biosciences, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.cogentbio.com

Market Cap $983.92M
PE -4
Debt $NaN
Cash $97.05M
EV $NaN
FCF -$192.10M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$242.30M
EBIT	-$260.43M
ROE	-77%
ROA	-68%
FCF	-$192.10M
Equity	$314.66M
Growth Stability	1
PE	-4.06
PB	3.13
P/FCF	-5.12
Price/Cash	0.1
Sales CAGR	1%
Equity CAGR	50%
Earnings Growth YoY	28%

Earnings Growth QoQ	20%
Sales CAGR 5Y	-0%
Equity CAGR 5Y	62%
Equity CAGR 3Y	19%
Market Cap	$983.92M
Assets	$384.02M
Cash	$97.05M
Shares Outstanding	101.44M
Working Capital	288.48M
Current Ratio	6.44
Shares Growth 3y	42%
Equity Growth QoQ	-16%
Equity Growth YoY	4%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

SEC Filings

Direct access to Cogent Biosciences, Inc. (COGT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Cogent Biosciences, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Cogent Biosciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Cogent Biosciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Cogent Biosciences, Inc..

Years

Calculation mode

= -$1.9B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$192M	-$192M	-$192M	-$192M	-$192M	-$192M	-$192M	-$192M	-$192M	-$192M	-$192M	-$1.9B
DCF		-$175M	-$159M	-$144M	-$131M	-$119M	-$108M	-$99M	-$90M	-$81M	-$74M	-$741M
Value	-$1.9B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-306%	-355%	-141%	-2K%	-	-	-	-
ROA	-	-42%	-65%	-33%	-33%	-49%	-66%	-68%
ROE	-	-57%	-100%	-76%	-34%	-55%	-75%	-77%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	16%	131%	-65%	-	-	-	-0%
Earnings YoY growth	-	35%	-8%	463%	-60%	94%	37%	-
Equity YoY growth	-	-223%	-47%	639%	-9%	19%	1%	62%
FCF YoY growth	-	24%	26%	-	-	108%	25%	-